Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
10 drugs in development
By Therapeutic Area
top 6
R&D Momentum
92/100
Pipeline Velocity
72/100
Trial Completion Rate
72/100
Pipeline Concentration
18/100
Pipeline Freshness
77/100
Strategic Signals
Activity
Last 14 days
Pre-Rehabilitation for Female Patients Undergoing Pelvic Radiotherapy
Prospective Validation of a Points Score System Predicting 30-day Survival for Patients With Metastatic Cancer Receiving Palliative Radiation Therapy
CGM Dynamic Index (CDI) for Predicting Prediabetes in People With Cystic Fibrosis
Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer
Enhancing Prospective Thinking in Early Recovery
Temporal Interference Methods for Addiction Treatment
Temporal Interference Methods for Non-invasive Deep Brain Stimulation
The Aging Brain Care Virtual Program
Increasing Equity in Lung Cancer Screening
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)